HANSABIOMED LIFE SCIENCES (HBM LS) IS PARTICIPATING IN THE FOLLOWING PROJECTS
funded under H2020 from European Commission:
MARVEL
Program name:
Coordinator: CONSIGLIO NAZIONALE DELLE RICERCHE
Full title/Goal:
MARVEL out-of-the-box solution is a paradigm shift from antibodies to peptides as an alternative class of affinity ligands characterized by high efficiency of EV capturing (Figure 2). In particular, MARVEL will introduce the use of membrane-sensing peptides (MSP) as novel ligands for the size-selective capturing of small EV, unbiased by differential surface protein expression (membrane as universal EV marker); in parallel, specific peptide probes (SPP) with high affinity for clinically relevant EV protein markers will be developed to enrich selective EV subpopulations. The versatility and modularity in scaling-up of the technology will be demonstrated on medium/large sample volumes in:
1) the manufacturing of GMP-compliant EV as a medicinal product for cardiac repair;
2) laboratory scale urine-based liquid biopsy for bladder cancer stratification and monitoring.
BOW
Program name: FET
Coordinator: Paolo Bergese, CSGI
Full Title/Goal:
The main objective of BOW is to create hybrid magnetic nanoparticles with a membrane surface made from an extracellular vesicle.
Within the BOW project HBM will participate in activities aimed at optimization of EV production, providing components such as EV depleted media, labelling reagents and protocols, and EV standards, as well as portable size focusing devices for SEC and TFF; Our team will contribute to comprehensive EV, and evMBDs characterization, and will ultimately verify and define minimal analytical package for definition of EV purity and quality (integrity, stability, and activity) to be assessed at each step of EV production scale up and engineering. Finally, HBM will perform in vitro tropism testing preceding definition of administration protocols for in vivo testing (doses and timeline).
TAIN-EV
Program name: ITN MSCA
Coordinator: Lorraine O'Driscoll, Trinity College Dublin
Full Title/Goal:
TRAINING in EXTRACELLULAR VESICLES: for benefit in Health and Disease HBM LS will evaluate and implement Costefficient high-throughput isolation methods; methods for characterizing EVs, applying bioinformatics analysis to extract biological meaning.
EAS
Internationalization of research and higher education, support for mobility and future generations
"Use of EVs isolated from plants of Estonian origin as natural plant protection products".
The aim of the project is to develop natural plant protection products / crop yield enhancers based on extracellular vesicles (EVs) isolated from Estonian plants.
Project no. 2014-2020.4.01.20-0303.
***
Product development support for the period 2014-2020
“Methods for Modification of Extracellular Vesicles (EVs) (EV-engineering)".
The aim of the project is to develop methodologies for the specific modification of extracellular vesicles (EVs) both before and after their secretion from cells. These technologies enable a company to provide services to produce EVs with specific properties that are i) tissue specific; (ii) used as carriers for medicinal products; (iii) for the calibration of instruments with specific markings.
Project no. EU60216. The cost of the project is 320,857 euros.
Program name: EVREM
Coordinator: Andres Salumets
Full Title/Goal: „Applied research for the extracellular vesicle-enabled non- invasive personalized
medicine testing and treatment for assisted reproduction and prenatal medicine (EVREM,
Extracellular Vesicles in REproductive Medicine)“
The main goal of EVREM is to carry out applied research, the results of which are the basis for the development of next-generation diagnostic tests in the field of reproductive and fetal medicine.
New tests (test sets and/or offered services) created as a result of development work evaluate:
• Uterine tissue quality (endometrial receptivity)
• IVF embryo quality/viability
• Presence of endometriosis
• Improve the current non-invasive prenatal testing NIPT technology to detect fetal genetic diseases.
Project no. 2014-2020.15.03.21-0127 (2014-2020.4.02.21-0398).
The project will be implemented during the period 01.11.2021-31.12.2023.
The total cost of the project is 1,763,800 euros, of which the grant is a maximum of 1,290,786 euros.